TXN Antibody

What is TXN and what cellular functions does it perform?

Thioredoxin (TXN) is a 12 kDa protein belonging to the thioredoxin family with a conserved catalytic domain (-Trp-Cys-Gly-Pro-Cys-Lys-) that exhibits reduction/oxidation (redox) activity. The protein exists in multiple forms, with TXN-1 (cytosolic/nuclear) and TXN-2 (mitochondrial) being the main members .

TXN functions include:

• Participation in various redox reactions through reversible oxidation of its active center dithiol to disulfide

• Catalyzing dithiol-disulfide exchange reactions

• Playing a role in reversible S-nitrosylation of cysteine residues in target proteins

• Nitrosylating the active site Cys of CASP3 in response to nitric oxide (NO), thereby inhibiting caspase-3 activity

• Inducing FOS/JUN AP-1 DNA-binding activity in ionizing radiation (IR) cells through its oxidation/reduction status

• Stimulating AP-1 transcriptional activity

TXN is multifunctional and widely studied due to its involvement in critical cellular processes related to oxidative stress and redox signaling.

What is the cellular localization of TXN and how does it change under different conditions?

TXN exhibits dynamic localization patterns that vary according to cellular conditions:

The protein's translocation between compartments is physiologically significant as it allows TXN to perform specific functions in different cellular locations . For instance, nuclear translocation after radiation exposure suggests a role in the cellular response to oxidative damage, while its secretion indicates potential paracrine or endocrine functions beyond the cell of origin.

What are the common applications of TXN antibodies in research?

TXN antibodies are versatile research tools employed across multiple applications:

When designing experiments, researchers should validate the antibody for their specific application, cell type, and species of interest as performance can vary significantly between different TXN antibodies .

How should researchers choose between monoclonal and polyclonal TXN antibodies?

The choice between monoclonal and polyclonal TXN antibodies should be based on the specific experimental requirements:

For techniques requiring high specificity (e.g., distinguishing closely related proteins), monoclonal antibodies like clone 2A7 are preferable. For applications where protein conformation might be altered (e.g., certain fixation methods), polyclonal antibodies recognizing multiple epitopes may provide better detection .

What validation methods should be employed to confirm TXN antibody specificity?

Thorough validation of TXN antibodies is essential for generating reliable research data:

• Western blotting validation:

  • Confirm detection of a single band at the expected molecular weight (~12 kDa for TXN)

  • Test in multiple relevant cell lines (e.g., HeLa, HepG2, MCF7)

  • Include positive controls known to express TXN

• Orthogonal validation:

  • Compare antibody results with mRNA expression data (e.g., RNAseq)

  • Correlate protein detection with gene expression levels across tissues

• Genetic validation:

  • Test in knockout/knockdown systems

  • Observe loss of signal in TXN-depleted samples

• Cross-reactivity testing:

  • Examine predicted species reactivity experimentally

  • Confirm specificity across human, mouse, rat samples if claiming multi-species reactivity

• Recombinant protein validation:

  • Test against purified recombinant TXN protein

  • Confirm detection of full-length protein vs. fragments

Commercial suppliers typically perform some validation (as seen in search results providing Western blot images), but researchers should conduct additional validation specific to their experimental system .

What epitope considerations are important when selecting a TXN antibody?

The epitope recognition of TXN antibodies significantly impacts their performance characteristics:

When investigating specific TXN functions, consider targeting relevant functional domains:

• The redox-active site (-Trp-Cys-Gly-Pro-Cys-Lys-) is critical for TXN's catalytic activity

• Antibodies recognizing this region may interfere with function in certain applications

• For detection of specific post-translational modifications, choose antibodies that do not compete with the modification site .

What are the optimal protocols for using TXN antibodies in Western blotting experiments?

For optimal Western blot detection of TXN:

• Sample preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Include reducing agents (e.g., DTT or β-mercaptoethanol) in sample buffer

  • Heat samples at 95°C for 5 minutes before loading

• Gel electrophoresis:

  • Use 12-15% polyacrylamide gels for optimal resolution of the 12 kDa TXN protein

  • Include molecular weight markers spanning 10-15 kDa range

• Transfer conditions:

  • Semi-dry or wet transfer (100V for 1 hour or 30V overnight)

  • Use PVDF membrane (0.2 μm pore size) for better retention of small proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Dilute primary antibody 1:1000-1:5000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-5 times with TBST

  • Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection:

  • Use enhanced chemiluminescence (ECL) substrate

  • For weak signals, consider using high-sensitivity ECL reagents

Based on search results, most commercial TXN antibodies show successful detection in human cell lines like HeLa, HepG2, and MCF7 with bands at the expected molecular weight of approximately 12 kDa .

How can TXN antibodies be optimized for immunohistochemistry applications?

For successful immunohistochemical detection of TXN:

• Tissue preparation:

  • Fix tissues in 10% neutral-buffered formalin

  • Paraffin embedding followed by sectioning at 4-5 μm thickness

  • For frozen sections, fix in cold acetone for 10 minutes

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Microwave or pressure cooker treatment for 10-20 minutes

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum

  • Dilute TXN antibodies typically at 1:50-1:200 for IHC applications

  • Incubate at 4°C overnight or 1-2 hours at room temperature

• Detection system:

  • Use biotin-streptavidin or polymer-based detection systems

  • Develop with DAB chromogen

  • Counterstain with hematoxylin

• Controls:

  • Include positive control tissues (verified samples include human liver cancer, human lung cancer)

  • Include negative controls (primary antibody omission)

TXN exhibits both cytoplasmic and nuclear staining patterns in IHC. The distribution pattern may vary depending on the tissue type and pathological conditions. Search results indicate that human liver cancer and lung cancer tissues have been successfully used as positive controls for TXN antibody validation in IHC applications .

What approaches can be used for immunoprecipitation experiments with TXN antibodies?

For effective immunoprecipitation of TXN:

• Lysis buffer selection:

  • Use non-denaturing lysis buffer (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 or Triton X-100)

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation

  • For redox studies, include N-ethylmaleimide to preserve disulfide bonds

• Pre-clearing:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Antibody binding:

  • Use 2-5 μg of TXN antibody per 500 μg of total protein

  • Incubate overnight at 4°C with gentle rotation

  • For monoclonal antibodies like clone 2A7, protein G beads are preferable

  • For rabbit polyclonal antibodies, protein A beads work well

• Precipitation and washing:

  • Add protein A/G magnetic beads and incubate for 1-2 hours

  • Collect beads using magnetic stand

  • Wash 3-5 times with lysis buffer (reducing salt concentration in final washes)

• Elution and analysis:

  • Elute proteins by boiling in SDS sample buffer

  • Analyze by Western blot using a different TXN antibody for detection if possible

For quantitative seroproteomics applications involving TXN antibodies, SILAC (Stable Isotope Labeling by Amino acids in Cell culture) techniques can be integrated with immunoprecipitation for differential analysis, as demonstrated in search result .

How can TXN antibodies be used to study redox signaling pathways?

TXN antibodies can be powerful tools for investigating redox signaling:

• Redox state detection:

  • Use non-reducing vs. reducing conditions in Western blotting to distinguish oxidized from reduced TXN

  • Alkylate free thiols before lysis to preserve in vivo redox state

  • Compare mobility shifts between oxidized and reduced forms

• Oxidation-specific co-immunoprecipitation:

  • Immunoprecipitate TXN under non-reducing conditions

  • Identify interacting partners specific to oxidized or reduced states

  • Combine with mass spectrometry to identify redox-dependent protein complexes

• Subcellular localization changes:

  • Use immunofluorescence with TXN antibodies to track translocation events

  • Monitor nuclear accumulation following oxidative stress

  • Quantify cytoplasmic-to-nuclear ratio changes in response to redox stimuli

• Target protein S-nitrosylation:

  • Study TXN's role in transferring NO groups to target proteins

  • Investigate the nitrosylation of CASP3 active site Cys by TXN

  • Combine with biotin-switch techniques to identify S-nitrosylated proteins

TXN plays a critical role in redox signaling through reversible oxidation of its active center dithiol and contributes to protein S-nitrosylation, making it a central player in cellular responses to oxidative stress and nitric oxide signaling .

What are the considerations when using TXN antibodies for studying post-translational modifications?

When investigating TXN post-translational modifications (PTMs):

• Epitope accessibility:

  • Select antibodies whose epitopes do not overlap with known/expected PTM sites

  • Consider using antibodies specifically designed to detect modified forms of TXN

• Sample preparation:

  • Include appropriate phosphatase inhibitors (for phosphorylation studies)

  • Add deacetylase inhibitors (for acetylation studies)

  • Use NEM or iodoacetamide to preserve thiol modifications

• Enrichment strategies:

  • Use phospho-specific antibodies for phosphorylated TXN

  • For oxidized TXN, consider differential alkylation approaches

  • For S-nitrosylated TXN, biotin-switch technique may be combined with TXN immunoprecipitation

• Detection methods:

  • 2D gel electrophoresis to separate TXN isoforms

  • Phos-tag gels for improved separation of phosphorylated forms

  • Mass spectrometry following immunoprecipitation for comprehensive PTM mapping

• Functional correlation:

  • Compare modified TXN localization patterns

  • Assess impact of PTMs on TXN enzymatic activity

  • Investigate PTM-dependent protein interactions

TXN undergoes various PTMs including oxidation, S-nitrosylation, glutathionylation, and phosphorylation, all of which can affect its function in redox regulation and signaling pathways .

How can researchers address challenges in cross-reactivity when using TXN antibodies across different species?

Managing cross-reactivity concerns with TXN antibodies:

• Sequence homology analysis:

  • TXN is highly conserved across species but contains some variable regions

  • Human TXN shows approximately 89% sequence identity with mouse and rat TXN

  • The sequence MVKQIESKTAFQEALDAAGDKLVVVDFSA is used as immunogen for some antibodies

• Validation in multiple species:

  • Test each antibody in lysates from different species

  • Confirm reactivity in Western blot, showing correct molecular weight (~12 kDa)

  • Verify subcellular localization patterns in immunofluorescence

• Epitope-specific considerations:

  • Antibodies targeting conserved domains (e.g., the catalytic -WCGPC- motif) are more likely to cross-react

  • C-terminal antibodies may show greater species specificity

  • For highly specific detection, consider species-specific epitopes

• Documented cross-reactivity:

  • Some antibodies like ABIN668871 (targeting AA 51-105) show validated reactivity with human, mouse, and rat

  • Other antibodies like ABIN563300 are specific to human TXN

  • Refer to manufacturer validation data for predicted reactivity

• Negative controls:

  • Include tissues/cells from TXN knockout models when available

  • Use pre-absorption controls with recombinant proteins from different species

When working with multiple species, researchers should carefully select antibodies with documented cross-reactivity or validate specificity in each species of interest .

What are the latest methodological advances in using TXN antibodies for biomarker discovery?

Recent methodological advances for TXN antibody-based biomarker research:

• Quantitative seroproteomics approaches:

  • SILAC-based quantitative immunoprecipitation using TXN antibodies

  • Detection of differentially produced antibodies against TXN in patient serum

  • Analysis of pre- and post-treatment antibody responses to identify predictive biomarkers

• Multiparameter tissue analysis:

  • Multiplex immunofluorescence incorporating TXN antibodies with other markers

  • Correlation of TXN expression with clinical outcomes in cancer tissues

  • Spatial analysis of TXN distribution in tumor microenvironment

• Liquid biopsy applications:

  • Detection of circulating TXN as potential biomarker

  • Analysis of autoantibodies against TXN in patient serum

  • Correlation with disease progression or treatment response

• High-throughput screening:

  • Antibody microarrays incorporating TXN antibodies

  • Automated image analysis of TXN immunohistochemistry in tissue microarrays

  • Machine learning approaches to identify TXN expression patterns associated with outcomes

Research has demonstrated that seroproteomics approaches using TXN antibodies can identify antibody biomarkers in pancreatic cancer patients, with potential applications in predicting treatment response and disease-free survival. For example, a study using SILAC-based quantitative immunoprecipitation identified differentially produced antibodies present in patient serum before and after GVAX therapy in pancreatic cancer .

What are common troubleshooting strategies for weak or absent TXN signal in Western blotting?

When encountering difficulties with TXN detection in Western blotting:

• Sample preparation issues:

  • Ensure complete lysis using appropriate buffer (RIPA or NP-40 with protease inhibitors)

  • Verify protein concentration using reliable methods (BCA or Bradford assay)

  • Increase sample loading (20-30 μg total protein may be required)

  • Check protein degradation by Ponceau S staining of membrane

• Antibody-related factors:

  • Optimize antibody dilution (try range from 1:500 to 1:5000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use fresh antibody aliquot (avoid repeated freeze-thaw cycles)

  • Consider alternative TXN antibody targeting different epitope

• Detection system optimization:

  • Use high-sensitivity ECL substrate for detection

  • Increase exposure time when imaging

  • Check secondary antibody compatibility and activity

  • Ensure proper blocking to reduce background interference

• Technical considerations:

  • For the small TXN protein (12 kDa), use higher percentage gels (12-15%)

  • Optimize transfer conditions for small proteins (lower methanol percentage)

  • Use PVDF membrane with smaller pore size (0.2 μm)

  • Consider semi-dry transfer for more efficient transfer of small proteins

• Positive controls:

  • Include lysate from HeLa, HepG2, or MCF7 cells as positive controls for TXN expression

  • Consider using recombinant TXN protein as a standard

Based on search results, most commercial TXN antibodies successfully detect the protein at approximately 12 kDa in human cell lines like HeLa, with recommended dilutions between 1:1000-1:5000 for Western blotting .

How can researchers address non-specific binding or high background with TXN antibodies?

To reduce non-specific binding and background issues:

• Blocking optimization:

  • Test different blocking agents (5% milk, 5% BSA, commercial blocking buffers)

  • Extend blocking time to 2 hours at room temperature

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Antibody dilution and incubation:

  • Use more dilute antibody solutions (start with manufacturer recommendations)

  • Prepare antibodies in fresh blocking buffer

  • Add 0.05-0.1% Tween-20 to antibody diluent

  • Consider shorter incubation times at room temperature instead of overnight

• Washing procedures:

  • Increase number of washes (5-6 times for 5-10 minutes each)

  • Use larger volumes of wash buffer

  • Include 0.1-0.5% Tween-20 in wash buffers

  • Add low concentration of salt (150-300 mM NaCl) to reduce ionic interactions

• Cross-adsorption:

  • For polyclonal antibodies with high background, consider cross-adsorption against tissue lysates

  • Pre-incubate diluted antibody with membrane containing non-target proteins

• Alternative antibody selection:

  • Monoclonal antibodies like clone 2A7 may provide lower background than polyclonal antibodies

  • Consider antibodies purified by affinity chromatography methods

  • Review validation images from manufacturers to assess background levels

Search results indicate that several TXN antibodies undergo affinity purification processes, which can help reduce non-specific binding. For example, ABIN7429172 undergoes antigen-specific affinity chromatography followed by Protein A affinity chromatography, while E-AB-12906 is purified by affinity purification methods .

What approaches help ensure reproducibility when using different lots of TXN antibodies?

To maintain experimental consistency across antibody lots:

• Validation protocol standardization:

  • Establish a standard validation protocol for each new antibody lot

  • Test new lots side-by-side with previously validated lots

  • Maintain positive control lysates/tissues as reference standards

  • Document optimal conditions for each lot

• Antibody characterization:

  • Request lot-specific validation data from manufacturers

  • Determine lot-specific optimal dilutions for each application

  • Assess potential variations in background levels between lots

  • Compare epitope recognition pattern in multiple sample types

• Reference sample banking:

  • Maintain aliquots of well-characterized positive control samples

  • Use consistent cell lines known to express TXN (e.g., HeLa, HepG2)

  • Create internal reference standards for quantitative applications

  • Store reference blot images for comparison

• Normalization strategies:

  • For quantitative Western blots, normalize to total protein (Ponceau S)

  • Include internal control proteins in multiplex immunofluorescence

  • Consider dual detection with alternative TXN antibody recognizing different epitope

  • Document batch effects and normalize across experiments

• Antibody selection considerations:

  • Monoclonal antibodies (e.g., clone 2A7, clone 3H3) typically show better lot-to-lot consistency

  • Recombinant antibodies like ZooMAb® provide higher reproducibility than traditional hybridoma-derived antibodies

  • Consider multiple suppliers or antibody types as backup options

Recombinant antibody technologies, such as the ZooMAb® recombinant rabbit monoclonal antibody against TXN mentioned in search result , are specifically designed to address lot-to-lot variation issues and provide more consistent performance across manufacturing batches.